Earnings Call · Q4 FY2023·2024-03-05

Q4 23EPS +100.00%*·Rev n/aQ3 23EPS +54.55%·Rev n/aQ2 23EPS +50.00%·Rev n/aQ1 23EPS +13.98%·Rev n/a⚠ consensus missing

RIGEL PHARMACEUTICALS INC RIGL

Ray Furey — Chief Executive Officer

Raul Rodriguez — President and CEO

Dave Santos — Chief Commercial Officer

Francois Di Trapani — Senior Vice President of Medical Affairs

Dean Schorno — Chief Financial Officer

+7.2%1d on move date+5.8% vs SPY3d−1.4%5d−3.6%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RIGL calls or request research access.

More RIGL calls Browse calls Request research access